For example, Bazedoxifene, agonist of estrogen receptor α, was used to treat postmenopausal osteoporosis via activating estrogen receptor α on osteoblast and osteocyte and increasing the ratio of OPG/RANKL to inhibit the activity of osteoclast (Brown, 2017). The gene discussed is TNFSF11; the disease is postmenopausal osteoporosis.